![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 49, 47551-47556, December 6, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, July 22, 2002, and in revised form, September 25, 2002
The presence of intracellular aggregates
that contain Cu/Zn superoxide dismutase (SOD1) in spinal cord motor
neurons is a pathological hallmark of amyotrophic lateral sclerosis
(ALS). Although SOD1 is abundant in all cells, its half-life in motor neurons far exceeds that in any other cell type. On the basis of the
premise that the long half-life of the protein increases the potential
for oxidative damage, we investigated the effects of oxidation on
misfolding/aggregation of SOD1 and ALS-associated SOD1 mutants.
Zinc-deficient wild-type SOD1 and SOD1 mutants were extremely prone to
form visible aggregates upon oxidation as compared with wild-type
holo-protein. Oxidation of select histidine residues that bind metals
in the active site mediates SOD1 aggregation. Our results provide a
plausible model to explain the accumulation of SOD1 aggregates in motor
neurons affected in ALS.
ALS1 is a fatal
neuromuscular disease that presents as weakness, spasticity, and muscle
atrophy. The disease is caused by selective degeneration of motor
neurons in the brain, brainstem, and spinal cord. Although ALS presents
mostly as a sporadic disease, a familial form of ALS is seen in ~10%
of cases. Twenty percent of familial ALS (FALS) cases are caused by
point mutations in the SOD1 gene. More than 90 distinct amino acid mutations spread throughout the sequence of
this 153-residue protein have been identified (1). The finding that
many FALS-associated SOD1 mutants possess full specific enzyme activity
(2) suggests that the disease is not caused by loss of normal dismutase
activity. Further support for this idea has come from transgenic mice
studies. Transgenic mice that harbor FALS-associated SOD1
mutations develop ALS-like symptoms despite having greater than normal
levels of SOD1 activity, including the normal complement of endogenous
mouse SOD1 enzyme (3). Furthermore, SOD1 knockout mice do
not develop ALS-like symptoms. Thus, it has been proposed that
mutations in SOD1 cause FALS by a gain, rather than a loss,
of function (reviewed in Ref. 1).
One proposed gain of function involves free radical generation by SOD1.
Because the dismutase action of SOD1 runs in a reversible catalytic
cycle with a number of different possible substrates (4-6), under some
conditions, SOD1 may catalyze the reverse reaction and generate radical
species. It has been proposed that certain FALS-associated SOD1
mutants have lower Km values for hydrogen peroxide
in the reverse reaction and therefore possess greater free radical
generating activity than do wild-type enzymes. This makeup
ultimately allows a greater number of cytotoxic peroxidation reactions
to occur in these mutants (4, 5).
The exact species responsible for oxidative damage, however, has
recently come under question. Fridovich and co-worker (7) showed that
the production of hydroxyl radicals would be negligible because of
competition with bicarbonate ions for hydroxyl radicals bound to copper
in SOD1.
Another possible gain of function implicates the formation of
zinc-deficient enzyme as the common toxic entity derived from all
mutants. One property shared by many FALS-associated SOD1 mutants is a
decreased affinity for Zn2+ (8, 9). It has been proposed
that reduced Zn2+ binding destabilizes the structure of
SOD1, increasing the rate of abnormal reduction of bound
Cu2+ to Cu+ by intracellular reducing agents.
This reduced form of SOD1 could then catalyze the reverse enzymatic
reaction and become a net producer of superoxide anion. In the absence
of a well defined protein fold, the electrostatic gradient that is
normally present in SOD1 (10) does not exist to prevent diffusion of
the resultant radical anion. Therefore, in the presence of nitric
oxide, which reacts five times faster with superoxide than does SOD1
itself, zinc-deficient SOD1 becomes a net producer of peroxynitrite
(11). Thus, the zinc-deficient SOD1 hypothesis maintains that
peroxynitrite is the final mediator of oxidative neuronal injury and
works by either nitrating and/or oxidizing critical cellular targets.
Active site copper plays a critical role in both of the proposed
mechanisms for a gain of function of FALS-associated SOD1 mutants
described above. A recent study that used transgenic mice that
expressed FALS-associated SOD1 mutants but lacked the gene for the
copper chaperone protein (CCS) investigated whether alterations in
copper loading would affect disease pathobiology (12). CCS facilitates
the incorporation of Cu2+ into SOD1 in vivo (13,
14), and copper is essential for normal dismutase activity as well as
for any gained functions that are oxidant-mediated. The transgenic
study found that knocking out the CCS gene reduced copper incorporation
into FALS-associated SOD1 mutants; however, disease onset and
progression in the mouse model was largely unaffected. The fact that
20-30% of total SOD1 activity remained in the absence of CCS prevents
this study (12) from completely ruling out copper-mediated mechanisms
of toxicity in SOD1 transgenic mice, but it does suggest
that other mechanisms such as protein aggregation may play an important
role in the overall cytotoxicity.
Another dramatic gain of function exhibited by SOD1 mutants is a very
high propensity to aggregate (3, 15). COS7 cells transfected with
FALS-associated SOD1 mutants produce cytoplasmic aggregates composed of
the SOD1 mutant protein; transfections of wild-type SOD1, on the other
hand, do not cause such cellular alterations (15). A number of
transgenic mice, all of which expressed a particular FALS-associated
SOD1 mutant and co-expressed different amounts of wild-type
SOD1, were shown to uniformly exhibit intracellular SOD
aggregation in neural tissue as well as ALS-like symptoms regardless of
whether wild-type SOD1 expression was elevated or eliminated (3). SOD1
aggregates have been proposed to produce toxicity by interference with
normal proteasome function (16) or by altering chaperone
(e.g. heat shock protein 70) (17, 18) activity.
In the present study, we sought to elucidate physiologically relevant
environmental factors that may trigger aggregation of SOD1 in motor
neurons. SOD1 aggregates seen in ALS patients and transgenic mouse
models are limited to neural tissue (motor neurons and, occasionally,
neighboring astrocytes) and are not seen in other cell types. Given
that SOD1 is present in high concentrations in all cells, an
environmental factor must exist within motor neurons that induces
aggregation specifically in this cell type. Two differences between
SOD1 molecules in motor neurons and other cells are its long half-life
and higher concentration. Concentration of SOD1 is greater in motor
neurons than in other neurons and glial cells, and it is found not only
in the cell body of motor neurons but also within axons and nerve
termini (19). To reach the nerve termini, SOD1 is transported through
the axon by using the slow component b of the anterograde axonal
transport system (20), which has a rate of 2-8 mm/day. Thus, the
transport time for motor neurons with a meter-long axon could approach
500 days, and the life span of the protein must exceed the transport
time. The long life span of this protein increases the chances of
oxidative modification by reactive oxygen species; one possible
byproduct of oxidative modification is induction of protein
aggregation. The greater life span of SOD1 in motor neurons means that
it would have more opportunity to accumulate oxidative modifications
and to be altered in ways that could increase its own production of abnormal oxidants (i.e. to become zinc-deficient and
catalyze the formation of peroxynitrite).2
Oxidative damage to SOD1, either
self-induced or the result of other oxidant sources, in turn may
trigger aggregation. In support of this hypothesis, markers of
oxidative damage were shown to be significantly elevated in neural
tissue of ALS patients as compared with controls (21, 22). To explore
the possibility that oxidation triggers SOD1 aggregation, we examined
the effects of oxidation on fully metallated wild-type SOD1
(holo-SOD1), on zinc-deficient SOD1, and on four SOD1 mutants.
In Vitro Aggregation of SOD1--
Wild-type Cu-Zn SOD1 from
human erythrocytes was obtained from Sigma. Mutant and
zinc-deficient SODs were prepared as described previously (9).
Oxidation reactions consisted of 10 µM SOD1, 4 mM ascorbic acid, and 0.2 mM CuCl2
in 10 mM Tris, 10 mM acetate buffer, whereas
control reactions were 10 µM SOD1 in buffer. Reactions were incubated at 37 °C for 48 h. The pH was 7.0 unless stated otherwise.
Inhibition of in Vitro Aggregation--
To readily recognize
inhibition of SOD1 aggregation, the most aggregation-prone SOD1 species
(zinc-deficient SOD1) was used. SOD1 aggregation mixtures (10 µM SOD1, 4 mM ascorbate, 0.2 mM CuCl2, 10 mM Tris acetate, pH 7) were incubated
with 2 mM EDTA, 10 mM mannitol, or 10 mM DMPO as probes for the reactive oxygen species.
Anaerobic conditions were achieved by degassing all solutions and
oxidizing them under vacuum (37 °C) in a vacuum hydrolysis tube (Pierce).
Right Angle Light Scattering--
Light scattering measurements
were made with a Photon Technology International QM-1 fluorescence
spectrophotometer. Excitation and emission wavelengths were set to 350 nm (bandpass = 4 nm).
Atomic Force Microscopy--
All images were obtained by using a
Digital Instruments NanoScope III© atomic force
microscope. Samples were deposited and dried onto freshly cleaved mica
under positive pressure. Contact-mode images were obtained by using a
Si3N4 tip (Digital Instruments) with a nominal
spring constant of 0.12 N/m.
Electron Microscopy--
Electon microscopy grids (Canemco,
Quebec, Canada) were floated on 10 µl drops of SOD1 samples, negative
stained with uranyl acetate (MecaLab Inc., Quebec, Canada), and
examined in an FEI Tecnai 12 transmission electron microscope (80 kV
accelerating voltage).
Amino Acid Analysis--
Amino acid compositions of oxidized and
control SOD1 were determined by using the Waters Picotag Amino Acid
Analysis system, which uses gas phase acid hydrolysis (6N
HCl, 120 °C), and either precolumn derivitization with
phenylisothiocyanate or postcolumn derivitization with ninhydrin.
Capillary Liquid Chromatography/Tandem Mass
Spectroscopy--
Peptides were analyzed by using a Q-TOF Ultima mass
spectrometer (Micromass, Manchester, UK) coupled to a capillary
high-pressure liquid chromatography. Peptides eluted by acetonitrile
were ionized by electrospray, and peptide ions were automatically
selected and fragmented in a data-dependent acquisition
mode. Data base searching was done with Mascot (Matrix Science).
ANS/Thioflavin T Binding--
10 µM SOD1 in 10 mM Tris acetate (pH 7.0) was incubated for 30 min with 20 µM ANS or 20 µM thioflavin T before
measuring emission spectrum (excitation at 372 and 450 nm, respectively).
Congo Red Spectral Shift Assay--
SOD1 aggregates were diluted
to a final concentration of 3 µM (~100 µg/ml) and
incubated with 6 µM Congo red for 30 min before measuring
near-UV and visible absorbance.
Circular Dichroism (CD)--
Zinc-deficient SOD1 aggregates were
centrifuged for 5 min at 13,000 × g, and the
supernatant was removed and replaced with 20 mM sodium
phosphate buffer, pH 7.0. Aggregates were then resuspended by vortex
and sonication before CD spectra were recorded on an Aviv CD
spectrometer model 62 DS at 25 °C.
Metal-catalyzed Oxidation of SOD1--
We used
metal-catalyzed oxidation with CuCl2 and ascorbic acid to
generate reactive oxygen species because of the physiological relevance
of this system. Metal-catalyzed oxidation is the principal source of
hydroxyl radicals under normal physiological conditions (23), and it is
especially important under conditions of oxidative stress (24). The
concentrations of ascorbic acid used in this study (2-4
mM) are well within the normal concentration range (0.5-10
mM) found in neurons and glial cells (25). We examined the
effects of oxidation on three different ALS-associated mutants of SOD1:
A4V, D90A, and G93A, as well as a site-directed mutant (D124N) that has
decreased zinc-binding affinity (26) and serves as a model of
zinc-deficient SOD1. A4V is the most common mutation that causes FALS,
D90A causes a rare autosomal recessive form of FALS (1), and G93A is
the mutant most widely used for the transgenic mouse model of ALS. We
examined the effect of oxidation on the zinc-deficient form of
wild-type SOD1, because this species has been implicated in
neurotoxicity associated with ALS (11) and because it can use ascorbate
to produce superoxide and hydrogen peroxide directly.
We find that at a neutral pH, oxidation of each of the three SOD1
mutants and zinc-deficient wild-type SOD1 induces the formation of
large aggregates that scatter light (Fig.
1A). The zinc-deficient protein displayed the most robust aggregation reaction and,
interestingly, D90A, the mutation that causes an autosomal recessive
form of FALS, displayed the least amount of aggregate formation.
Oxidation of wild-type SOD1 under identical conditions did not induce
the formation of aggregates detectable by right-angle light scattering (i.e. visible aggregates >350 nm in diameter). With the
exception of zinc-deficient SOD1, aggregates did not form in control
samples that lacked oxidants. The small amount of aggregate observed in control samples of zinc-deficient protein suggests that this form of
the protein has an intrinsic aggregation tendency. The aggregation reaction displays distinct pH dependence, with reduced aggregation at
pH < 5.5 (Fig. 1B). Similar pH dependence has been
observed in the oxidation-induced aggregation of human relaxin, in
which oxidation of a single His residue apparently accounts for the pH
dependence (27). Performance of the oxidation reaction under anaerobic
conditions or in the presence of EDTA inhibited aggregation and
revealed that copper and oxygen are an absolute requirement for
oxidation-induced aggregation (Fig. 1C). On the other hand, the addition of the free radical scavengers mannitol and DMPO did not
inhibit aggregation (Fig. 1C). Similar results have been obtained with copper-catalyzed, oxidation-induced aggregation of both
human relaxin (28) and hamster prion protein (29). The insensitivity to
free radical scavengers and the pH dependence of the oxidation-induced
aggregation are consistent with the site-specific metal-catalyzed
oxidation mechanism. This mechanism requires a metal ion binding site
that is in close spatial proximity to the modification sites (23). In
this type of oxidation reaction, very few residues are modified.
Characterization of Oxidative Modification Sites--
Amino acid
analysis was performed on oxidized wild-type protein and on oxidized
and aggregated zinc-deficient SOD1 (Table I
). The most striking feature of the amino
acid analysis of both types of oxidized protein was the loss of
histidine residues. Amino acid analysis suggested that three of the
eight histidine residues of the SOD1 subunit were modified. It is known
that metal-catalyzed oxidation of proteins leads to conversion of
histidine residues to 2-oxohistidine, 4-hydroxy-glutamate, aspartate,
or asparagine (23). Because the glutamate and aspartate contents do not
appear to be altered by oxidation, it is likely that histidines have been largely converted to 2-oxohistidines. Further support for the
conversion to 2-oxohistidine was obtained by sequencing tryptic peptides of oxidized wild-type SOD1 by LC-MS/MS (Table
II). The masses of two tryptic peptides
were increased by 16 mass units, which is consistent with the formation
of 2-oxohistidine. Peptide sequencing revealed that both His 80 and His
120 contain an additional 16 mass units; these residues are located at
the zinc and copper binding sites, respectively, of SOD1 (Fig.
2).
Morphology and Structure of SOD1 Aggregates--
The results
presented here demonstrate that oxidation of select His residues
induces misfolding and aggregation of SOD1. However, the question
remains, do these in vitro aggregates represent aggregates seen in ALS? Examination of ALS inclusion bodies by light, electron, and immunoelectron microscopy have shown them to be a unique feature of
ALS and distinct from the amyloid plaques and neurofibrillary tangles
seen in Alzheimer's disease and the intracellular deposits seen in
Parkinson's disease (30-32). In particular, ALS inclusion bodies are
not stained by the amyloid dye Congo red (30). Instead, the inclusion
bodies seen in COS7 cells that express ALS mutants of SOD1 (15),
transgenic mouse models of ALS (3, 33), and ALS patients (34-37) are
all composed of a mixture of granular aggregates and some thick fibers
as compared with the thin fibrils seen in amyloid diseases (38).
Our atomic force microscopy examination of aggregates formed by
oxidation of zinc-deficient SOD1 revealed large amorphous aggregates
(<10 µm diameter) that were composed of smaller globular particles
(0.2-0.5 µm diameter) (Fig.
3A) reminiscent of in
vivo inclusion bodies (34-37). Incubation of oxidized wild-type
protein at pH 5 produced a scant number of aggregates that could be
detected by negative staining electron microscopy. These heterogeneous aggregates were composed of amorphous aggregates along with fibrous aggregates that were 40 nm in diameter and several micrometers long
(Fig. 3B). These fibrous aggregates are thicker than the amyloid fibrils formed by the Alzheimer amyloid peptide, which are
60-90 Å in diameter (38).
Dye binding experiments with thioflavin T and Congo red, as well as CD,
were also used to determine whether the SOD1 aggregates possessed
amyloid characteristics. A 2-fold enhancement of thioflavin T
fluorescence was observed with the aggregates produced from zinc-deficient SOD1 (Fig. 4A);
however, the fluorescence enhancement seen with amyloid fibrils is
usually 3 orders of magnitude higher (39). On binding to Congo
red, very little, if any, increase was seen in absorbance or spectral
shift (Fig. 4B), which would have been expected had the aggregates in
fact been amyloid (40). This lack of increase is in keeping with
the failure of Congo red to bind SOD inclusion bodies in
vivo (30).
The CD spectrum of SOD1 undergoes a large change on
oxidation-induced aggregation (Fig. 4C). However, the CD spectrum of
SOD1 aggregates indicates random coil rather than the characteristic Structural Changes to SOD1 before Aggregation--
To determine
whether susceptibility to oxidation-induced aggregation of
zinc-deficient SOD1 and SOD1 mutants results from an altered
conformation, ANS dye binding experiments were performed on untreated
unoxidized protein samples. ANS binding is a probe of exposed
hydrophobic surfaces in proteins. Zinc-deficient SOD1 bound the most
ANS, wild-type SOD1 did not show any ANS binding, and the SOD1 mutants
displayed varying intermediate degrees of ANS binding (Fig.
5). It is known that the bound zinc in
SOD1 helps maintain the structure of the active site and is not
directly involved in catalysis, and removal of zinc destabilizes the
enzyme (41). The ANS binding experiments indicate that in addition to
general destabilization, an alteration in conformation that leads to
exposure of hydrophobic surface is also associated with zinc removal.
The intermediate levels of ANS binding observed with the SOD1 mutants
may have resulted from an altered looser conformation of the protein in
solution, as has been suggested by the crystal structures of
mutant SOD1 (42). Alternatively, the intermediate ANS binding may
result from heterogeneity in the metallation status of the mutants, in
which mutant preparations that show the greatest ANS binding contain
significant quantities of incompletely metallated protein, much of
which could be zinc-deficient.
Concluding Remarks--
We have shown that zinc-deficient SOD1, a
site-directed mutant with low zinc binding affinity, low zinc content
(D124N), and three FALS-associated SOD1 mutants, is much more
susceptible to oxidation-induced aggregation than the fully metallated
wild-type protein. These findings, coupled with the long half-life of
SOD1 in motor neurons and the high levels of oxidative damage that are
known to occur in neural tissues of ALS patients (21), provide a
possible explanation for the SOD1 aggregates observed in ALS. Although
it still remains to be established whether the SOD1 aggregates are
intrinsically toxic, evidence is mounting that protein aggregates exhibit a general toxicity that is independent of the function of the
protein in its native state (43). Our data are also consistent with the
recent model put forward by Okado- Matsumoto and Fridovich (18) in
which antiapoptotic factors such as heat shock proteins are
sequestered by abundant misfolded/aggregated proteins, such as SOD1 or other misfolded proteins induced by oxidation/nitration, leading to apoptosis.
We thank Dr. Harry Ledebur, Dr. Irene
Mazzoni, Dr. Jennifer Griffin, and Eric Thibaudeau for
helpful discussions and Dr. Clarissa Desjardins and Lloyd Segal for
encouragement and support. We thank Dr. Yingxin Zhuang for rigorous and
meticulous efforts to produce consistently high-quality purified SOD1
preparations that proved vital to our studies. We also thank Dr. I. Fridovich for critical evaluation of this work.
*
This work was supported by grants from Caprion
Pharmaceuticals Inc., Temerty Family Foundation (to N. R. C.), and
Canadian Institutes of Health Research (to A. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
N. R. C. holds the Jeno and Ilona Diener Chair of
Neurodegenerative Diseases.
Published, JBC Papers in Press, September 27, 2002, DOI 10.1074/jbc.M207356200
2
M. J. Strong, W. L. Strong, B. P. He, M. M. Sopper, and J. P. Crow, personal communication.
The abbreviations used are:
ALS, amyotrophic
lateral sclerosis;
FALS, familial amyotrophic lateral sclerosis;
SOD1, Cu/Zn superoxide dismutase;
CCS, copper chaperone protein;
ANS, 8-anilino-1-napthalene-sulfonic acid;
DMPO, 5,5-dimethyl-1-pyrroline-N-oxide.
Oxidation-induced Misfolding and Aggregation of
Superoxide Dismutase and Its Implications for Amyotrophic Lateral
Sclerosis*
,
,
**,

Departments of Medical Biophysics and
Biochemistry, Ontario Cancer Institute, University of Toronto, Toronto,
Ontario M5G 2M9, Canada, § Caprion Pharmaceuticals, Inc.,
St. Laurent, Quebec H4S 2C8, Canada, ¶ Departments of
Anesthesiology, Pharmacology/Toxicology, and Biochemistry and Molecular
Genetics, University of Alabama, Birmingham, Alabama 35294, and
Centre for Research in Neurodegenerative Diseases and Sunnybrook
and Women's College Health Sciences Centre, University of
Toronto, Toronto, Ontario M5S 3H2, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Zinc-deficient and mutant SODs form visible
aggregates on oxidation, whereas the wild-type protein does not.
A, comparison of right-angle scattering signals from various
SOD1 solutions on oxidation with 4 mM ascorbate and 0.2 mM CuCl2 (black) versus
control (gray) at 37 °C, pH 7.0, for 48 h.
Dotted line indicates scattering produced by 10 mM Tris acetate buffer with 4 mM ascorbate and
0.2 mM CuCl2. B, pH dependence of
oxidation-induced aggregation of SOD. Zinc-deficient SOD1 forms visible
aggregates over a large pH range (5.0-7.5) on oxidation
(triangles). Wild-type SOD1 does not form visible aggregates
under similar conditions (circles). Zinc-deficient SOD1
controls also yielded greater than base-line scattering
(squares). C, light-scattering signal of
zinc-deficient SOD1 treated with copper/ascorbate oxidation under
various inhibition conditions (for details, see "Experimental
Procedures"). Anaerobic conditions and copper removal by EDTA
chelation prevents aggregation, whereas free radical scavengers
(mannitol and DMPO) do not. Light-scattering measurements were made
with a PTI QM-1 fluorimeter. Excitation and emission wavelengths were
set to 350 nm (bandpass = 2 nm).
Comparison of relative amino acid composition of oxidized to
control SOD1

View larger version (27K):
[in a new window]
Fig. 2.
Oxidative modification sites of SOD1 revealed
by tryptic digestion and mass spectrometry. SOD (30 µM) was incubated with 2 mM ascorbate, 25 µM copper, 10 mM sodium acetate, pH 5.0, at
37 °C for 24 h. The protein was reduced and alkylated with
dithiothreitol and iodoacetamide in 6 M guanidine
hydrochloride and then digested with trypsin (25:1 substrate to enzyme
ratio) at 38 °C for 50 h and analyzed by capillary LC-MS/MS.
The ribbon diagram was created from the PDB coordinates 1SPD
with use of the program PYMOL (Delano Scientific). Side chains
of modified His residues (80 and 120) are orange, the copper
ion is blue, and the zinc ion is gray.

View larger version (76K):
[in a new window]
Fig. 3.
A, atomic force microscope height image
of an aggregate formed by zinc-deficient SOD1. Aggregates are large and
amorphous. Horizontal scale bar = 10 µm,
vertical scale = 2 µm. Inset: close-up of
protein aggregate shows that the aggregate is made up of smaller
particles. Horizontal scale bar = 2 µm,
vertical scale = 1 µm. B, transmission
electron micrograph of SOD1 incubated in the presence of 25 µM copper and 2 mM ascorbate in 10 mM sodium acetate buffer, pH 5.0, for 48 h at
37 °C. Scale bar = 400 nm.

View larger version (16K):
[in a new window]
Fig. 4.
A, comparison of thioflavin T binding of
zinc-deficient SOD aggregates (thin line) and wild-type SOD
(thick line). Ten µM SOD1 in 10 mM
Tris acetate (pH 7.0) was incubated with 20 µM thioflavin
T before the emission spectrum was measured (excitation at 450 nm).
Although some increase occurred in observed fluorescence intensity, it
is far less than the increase typically seen on thioflavin T binding to
amyloid fibrils. The increase observed is attributed to sequestering of
the fluorophore from quenchers. B, spectral shift assay of
aggregates with the use of Congo red. Six µM Congo red
(solid line) had comparable absorbance to 3 µM SOD and 6 µM Congo red (dotted line). C, CD
spectra of SOD aggregates (solid line) and native SOD
(dotted line). SOD aggregates do not contain a high
proportion of
-sheet structures and, with the dye binding
experiments, this indicates that these aggregates are likely not
amyloid.
-sheet spectrum of amyloid. Thus, although it appears that oxidative damage of SOD1 results in misfolding and aggregation, the resultant aggregates do not appear to be amyloid. Indeed, the morphology of the
aggregates observed in vitro in this study compare favorably with that of granular SOD1 inclusions observed in ALS models and patients.

View larger version (24K):
[in a new window]
Fig. 5.
Comparison of ANS-binding of wild-type
(filled circles) to mutant (dashed
lines) and zinc-deficient SOD1 (open
circles). Ten µM SOD1 in 10 mM Tris acetate (pH 7.0) was incubated with 20 ANS before
the emission spectrum was measured (excitation at 372 nm). Blue shift
and increased intensity of ANS fluorescence in mutants and
zinc-deficient SOD1 indicates increased exposure of hydrophobic
domains. Inset: integrated ANS fluorescence signal from
mutant and zinc-deficient SODs compared with ANS fluorescence of
wild-type SOD1 (dashed line).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

To whom correspondence should be addressed. E-mail:
chakrab@ uhnres.utoronto.ca.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Cleveland, D. W.,
and Rothstein, J. D.
(2001)
Nat. Neurosci.
2,
806-819[CrossRef][Medline]
[Order article via Infotrieve]
2.
Borchelt, D. R.,
Lee, M. K.,
Slunt, H. S.,
Guarnieri, M., Xu, Z. S.,
Wong, P. C.,
Brown, R. H., Jr.,
Price, D. L.,
Sisodia, S. S.,
and Cleveland, D. W.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
8292-8296 3.
Bruijn, L. I.,
Houseweart, M. K.,
Kato, S.,
Anderson, K. L.,
Anderson, S. D.,
Ohama, E.,
Reaume, A. G.,
Scott, R. W.,
and Cleveland, D. W.
(1998)
Science
281,
1851-1854 4.
Yim, M. B.,
Kang, J.,
Yim, H.,
Kwak, H.,
Chock, P. B.,
and Stadtman, E. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5709-5714 5.
Wiedau-Pazos, M.,
Goto, J. J.,
Rabizadeh, S.,
Gralla, E. D.,
Roe, J. A.,
Valentine, J. S.,
and Bredesen, D. E.
(1996)
Science
271,
515-518[Abstract]
6.
Liochev, S. I.,
and Fridovich, I.
(2002)
Arch. Biochem. Biophys.
402,
166-171[CrossRef][Medline]
[Order article via Infotrieve]
7.
Liochev, S. I.,
and Fridovich, I.
(2002)
J. Biol. Chem.
277,
34674-34678 8.
Lyons, T. J.,
Hongbin, L.,
Joy, J. G.,
Nersissian, A.,
Roe, J. A.,
Graden, J. A.,
Café, C.,
Ellerby, L. M.,
Bredesen, D. E.,
Gralla, E. B.,
and Valentine, J. S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12240-12244 9.
Crow, J. P., Ye, Y. Z.,
Strong, M.,
Kirk, M.,
Barnes, S.,
and Beckman, J. S.
(1997)
J. Neurochem.
69,
1936-1944[Medline]
[Order article via Infotrieve]
10.
Klapper, I.,
Hagstrom, R.,
Fine, R.,
Sharp, K.,
and Honig, B.
(1986)
Proteins.
1,
47-59[CrossRef][Medline]
[Order article via Infotrieve]
11.
Estevez, A. G.,
Crow, J. P.,
Sampson, J. B.,
Reiter, C.,
Zhuang, Y.,
Richardson, G. J.,
Tarpey, M. M.,
Barbeito, L.,
and Beckman, J. S.
(1999)
Science
286,
2498-2500 12.
Subramanium, J. R.,
Lyons, E. W.,
Liu, J.,
Bartnikas, T. B.,
Rothstein, J.,
Price, D. L.,
Cleveland, D. W.,
Gitlin, J. D.,
and Wong, P. C.
(2002)
Nat. Neurosci.
5,
301-307[CrossRef][Medline]
[Order article via Infotrieve]
13.
Culotta, V. C.,
Klomp, L. W.,
Strain, J.,
Casareno, R. L.,
Krems, B.,
and Gitlin, J. D.
(1997)
J. Biol. Chem.
272,
23469-23472 14.
Wong, P. C.,
Waggoner, D.,
Subramaniam, J. R.,
Tessarollo, L.,
Bartnikas, T. B.,
Culotta, V. C.,
Price, D. L.,
Rothstein, J.,
and Gitlin, J. D.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
2886-2891 15.
Koide, T.,
Igarashi, S.,
Kikugawa, K.,
Nakano, R.,
Inuzuka, T.,
Yamada, M.,
Takahashi, H.,
and Tsuji, S.
(1998)
Neurosci. Lett.
257,
29-32[CrossRef][Medline]
[Order article via Infotrieve]
16.
Johnston, J. A.,
Dalton, M. J.,
Gurney, M. E.,
and Kopito, R. R.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12571-12576 17.
Bruening, W.,
Roy, J.,
Giasson, B.,
Figlewicz, D. A.,
Mushynski, W. E.,
and Durham, H. D.
(1999)
J. Neurochem.
72,
693-699[CrossRef][Medline]
[Order article via Infotrieve]
18.
Okado-Matsumoto, A.,
and Fridovich, I.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
9010-9014 19.
Pardo, C. A., Xu, Z.,
Borchelt, D. R.,
Price, D. L.,
Sisodia, S.,
and Cleveland, D. W.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
954-958 20.
Borchelt, D. R.,
Wong, P. C.,
Becher, M. W.,
Pardo, C. A.,
Lee, M. K., Xu, Z. S.,
Thinakaran, G.,
Jenkins, N. A.,
Copeland, N. G.,
Sisodia, S. S.,
Cleveland, D. W.,
Price, D. L.,
and Hoffman, P. N.
(1998)
Neurobiol. Dis.
5,
27-35[CrossRef][Medline]
[Order article via Infotrieve]
21.
Bowling, A. C.,
Schulz, J. B.,
Brown, R. H., Jr.,
and Beal, M. F.
(1993)
J. Neurochem.
61,
2322-2325[Medline]
[Order article via Infotrieve]
22.
Ferrante, R. J.,
Browne, S. E.,
Shinobu, L. A.,
Bowling, A. C.,
Baik, M. J.,
MacGarvey, U.,
Kowall, N. W.,
Brown, R. H.,Jr.,
and Beal, M. F.
(1997)
J. Neurochem.
69,
2064-2074[Medline]
[Order article via Infotrieve]
23.
Stadtman, E. R.,
and Berlett, B. S.
(1997)
Chem. Res. Toxicol.
10,
485-494[CrossRef][Medline]
[Order article via Infotrieve]
24.
Stadtman, E. R.
(1993)
Annu. Rev. Biochem.
62,
797-821[CrossRef][Medline]
[Order article via Infotrieve]
25.
Rice, M.
(2000)
Trends. Neurosci.
23,
209-216[CrossRef][Medline]
[Order article via Infotrieve]
26.
Banci, L.,
Bertini, I.,
Cabelli, D. E.,
Hallewell, R. A.,
Tung, J. W.,
and Viezzoli, M. S.
(1991)
Eur. J. Biochem.
196,
123-128[Medline]
[Order article via Infotrieve]
27.
Khossravi, M.,
Shire, S. J.,
and Borchardt, R. T.
(2000)
Biochemistry
39,
5876-5885[CrossRef][Medline]
[Order article via Infotrieve]
28.
Li, S.,
Nguyen, T. H.,
Schoneich, C.,
and Borchardt, R. T.
(1995)
Biochemistry
34,
5762-5772[CrossRef][Medline]
[Order article via Infotrieve]
29.
Requena, J. R.,
Groth, D.,
Legname, G.,
Stadtman, E. R.,
Pruisner, S. B.,
and Levine, R. L.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7170-7175 30.
Okamoto, K.,
Hirai, S.,
Yamazaki, T.,
Sun, X.,
and Nakazato, Y.
(1991)
Neurosci. Lett.
129,
233-236[CrossRef][Medline]
[Order article via Infotrieve]
31.
Hudson, A. J.
(1981)
Brain
104,
217-247 32.
Sillevis Smitt, P. A. E.,
Troost, D.,
Louwerse, E. S., De,
Jong, J. M. B. V.,
Van Kessel, D. T. P.,
and De Leeuw, M. A.
(1993)
Clin. Neuropathol.
12,
88-91[Medline]
[Order article via Infotrieve]
33.
Bruijn, L. I.,
Becher, M. W.,
Lee, M. K.,
Anderson, K. L.,
Jenkins, N. A.,
Copeland, N. G.,
Sisodia, S. S.,
Rothstein, J. D.,
Borchelt, D. R.,
Price, D. L.,
and Cleveland, D. W.
(1997)
Neuron
18,
327-338[CrossRef][Medline]
[Order article via Infotrieve]
34.
Kato, S.,
Shimoda, M.,
Watanabe, Y.,
Nakashima, K.,
Takahashi, K.,
and Ohama, E.
(1996)
J. Neuropathol. Exp. Neurol.
55,
1089-1101[Medline]
[Order article via Infotrieve]
35.
Kato, S.,
Hayashi, H.,
Nakashima, K.,
Nanba, E.,
Kato, M.,
Hirano, A.,
Nakano, I.,
Asayama, K.,
and Ohama, E.
(1997)
Am. J. Pathol.
151,
611-620[Abstract]
36.
Kato, S.,
Horiuchi, S.,
Nakashima, K.,
Hirano, A.,
Shibata, N.,
Nakano, I.,
Saito, M.,
Kato, M.,
Asayama, K.,
and Ohama, E.
(1999)
Acta Neuropathol.
97,
260-266[CrossRef][Medline]
[Order article via Infotrieve]
37.
Kato, S.,
Nakashima, K.,
Horiuchi, S.,
Nagai, R.,
Cleveland, D. W.,
Liu, J.,
Hirano, A.,
Takikawa, M.,
Kato, M.,
Nakano, I.,
Sakoda, S.,
Asayama, K.,
and Ohama, E.
(2001)
Neuropathology
21,
67-81[CrossRef][Medline]
[Order article via Infotrieve]
38.
Kirschner, D. A.,
Inouye, H.,
Duffy, L. K.,
Sinclair, A.,
Lind, M.,
and Selkoe, D. J.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
6953-6957 39.
Levine, H., III
(1993)
Protein Sci.
2,
404-410[Abstract]
40.
Klunk, W. E.,
Jacob, R. F.,
and Mason, R. P.
(1999)
Methods Enzymol.
309,
285-304[Medline]
[Order article via Infotrieve]
41.
Rodriguez, J. A.,
Valentine, J. S.,
Eggers, D. K.,
Roe, J. A.,
Tiwari, A.,
Brown, R. H., Jr.,
and Hayward, L. J.
(2002)
J. Biol. Chem.
277,
15932-15937 42.
Hart, P. J.,
Pellegrini, M.,
Nersissian, A. M.,
Gralla, E. B.,
Valentine, J. S.,
and Eisenberg, D.
(1998)
Protein Sci.
7,
545-555[Abstract]
43.
Bucciantini, M.,
Giannoni, E.,
Chiti, F.,
Baroni, F.,
Formigli, L.,
Zurdo, J.,
Taddel, N.,
Ramponi, G.,
Dobson, C. M.,
and Stefani, M.
(2002)
Nature
416,
483-484[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E. Herczenik and M. F. B. G. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J, July 1, 2008; 22(7): 2115 - 2133. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Urushitani, S. A. Ezzi, A. Matsuo, I. Tooyama, and J.-P. Julien The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS FASEB J, July 1, 2008; 22(7): 2476 - 2487. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Shaw, H. L. Lelie, A. Durazo, A. M. Nersissian, G. Xu, P. K. Chan, E. B. Gralla, A. Tiwari, L. J. Hayward, D. R. Borchelt, et al. Detergent-insoluble Aggregates Associated with Amyotrophic Lateral Sclerosis in Transgenic Mice Contain Primarily Full-length, Unmodified Superoxide Dismutase-1 J. Biol. Chem., March 28, 2008; 283(13): 8340 - 8350. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fujiwara, M. Nakano, S. Kato, D. Yoshihara, T. Ookawara, H. Eguchi, N. Taniguchi, and K. Suzuki Oxidative Modification to Cysteine Sulfonic Acid of Cys111 in Human Copper-Zinc Superoxide Dismutase J. Biol. Chem., December 7, 2007; 282(49): 35933 - 35944. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gruzman, W. L. Wood, E. Alpert, M. D. Prasad, R. G. Miller, J. D. Rothstein, R. Bowser, R. Hamilton, T. D. Wood, D. W. Cleveland, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis PNAS, July 24, 2007; 104(30): 12524 - 12529. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Banci, I. Bertini, A. Durazo, S. Girotto, E. B. Gralla, M. Martinelli, J. S. Valentine, M. Vieru, and J. P. Whitelegge Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: A possible general mechanism for familial ALS PNAS, July 3, 2007; 104(27): 11263 - 11267. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Taylor, B. F. Gibbs, E. Kabashi, S. Minotti, H. D. Durham, and J. N. Agar Tryptophan 32 Potentiates Aggregation and Cytotoxicity of a Copper/Zinc Superoxide Dismutase Mutant Associated with Familial Amyotrophic Lateral Sclerosis J. Biol. Chem., June 1, 2007; 282(22): 16329 - 16335. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Wen, V. Bhatia, V. L. Popov, and N. J. Garg Phenyl-{alpha}-tert-Butyl Nitrone Reverses Mitochondrial Decay in Acute Chagas' Disease Am. J. Pathol., December 1, 2006; 169(6): 1953 - 1964. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Broom, K. E. Auwarter, J. Ni, D. E. Russel, L.-A. Yeh, M. M. Maxwell, M. Glicksman, A. G. Kazantsev, and R. H. Brown Jr Two Approaches to Drug Discovery in SOD1-Mediated ALS J Biomol Screen, October 1, 2006; 11(7): 729 - 735. [Abstract] [PDF] |
||||
![]() |
P. Eli and A. Chakrabartty Variants of DsRed fluorescent protein: Development of a copper sensor. Protein Sci., October 1, 2006; 15(10): 2442 - 2447. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Matsumoto, S. Kim, and R. I. Morimoto Huntingtin and Mutant SOD1 Form Aggregate Structures with Distinct Molecular Properties in Human Cells J. Biol. Chem., February 17, 2006; 281(7): 4477 - 4485. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tiwari, Z. Xu, and L. J. Hayward Aberrantly Increased Hydrophobicity Shared by Mutants of Cu,Zn-Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis J. Biol. Chem., August 19, 2005; 280(33): 29771 - 29779. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Kim, R. Nakatomi, T. Akagi, T. Hashikawa, and R. Takahashi Unsaturated Fatty Acids Induce Cytotoxic Aggregate Formation of Amyotrophic Lateral Sclerosis-linked Superoxide Dismutase 1 Mutants J. Biol. Chem., June 3, 2005; 280(22): 21515 - 21521. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Furukawa and T. V. O'Halloran Amyotrophic Lateral Sclerosis Mutations Have the Greatest Destabilizing Effect on the Apo- and Reduced Form of SOD1, Leading to Unfolding and Oxidative Aggregation J. Biol. Chem., April 29, 2005; 280(17): 17266 - 17274. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Casoni, M. Basso, T. Massignan, E. Gianazza, C. Cheroni, M. Salmona, C. Bendotti, and V. Bonetto Protein Nitration in a Mouse Model of Familial Amyotrophic Lateral Sclerosis: POSSIBLE MULTIFUNCTIONAL ROLE IN THE PATHOGENESIS J. Biol. Chem., April 22, 2005; 280(16): 16295 - 16304. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Takamiya, M. Takahashi, Y. S. Park, Y. Tawara, N. Fuj |